|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1D-Adrenergic Receptor Induces Vascular Smooth Muscle Apoptosis via a p53-Dependent MechanismDepartments of Molecular and Biomedical Pharmacology (M.L.G.-C., J.L.S., M.T.P.) and Toxicology (D.K.St.C.), University of Kentucky, Lexington, Kentucky
Activation of the endogenous
1-adrenergic receptor (AR) associated with human aortic smooth muscle cells resulted in a dose- and time-dependent increase in the levels of mitochondrial reactive oxygen species (ROS). ROS increases were apparent within 10 min and maximal after 45 min. Prolonged activation (>4h) of the
1-AR resulted in smooth muscle cell apoptosis. Both the increase in ROS and apoptotic cell death were blocked by the nonselective
1-AR antagonist prazosin as well as the selective
1D-AR antagonist 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7, 9-dione (BMY 7378). Increases in ROS and apoptosis produced by
1-AR activation were also blocked by the p38 mitogen-activated protein kinase inhibitor 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole (SB 202190) and the NAPDH oxidase inhibitor apocynin. The extracellular signal-regulated kinase 1/2 inhibitor 2'-amino-3'-methoxyflavone (PD 98059) or the c-Jun NH2-terminal kinase inhibitor 1, 9-pyrazoloanthrone anthra(1, 9-cd)pyrazol-6(2H)-one (SP 600125) was without effect on increases in ROS levels or apoptosis. Pifithrin-
, an inhibitor of the tumor suppressor protein p53, had no effect on ROS generation but did block
1D-AR-induced apoptosis. Activation of the
1D-AR resulted in translocation of p53 to the mitochondria. The mitochondrial translocation of p53 was blocked by prazosin, BMY 7378, apocynin, SB 202190, and pifithrin-
. Apoptosis was also blocked by small interfering RNA directed against p53. These data show that the
1D-AR is coupled to the generation of mitochondrial ROS by a pathway involving p38 and NADPH oxidase. Sustained activation of the
1D-AR results in smooth muscle cell apoptosis in a pathway that involves the tumor suppressor protein p53 and the mitochondrial translocation of p53. The data also provide evidence of a linkage between the
1D-AR and p53.
Address correspondence to: Dr. Michael T. Piascik, Department of Molecular and Biomedical Pharmacology, The University of Kentucky College of Medicine, 800 Rose St., UKMC MS 305, Lexington, KY 40536-0084. E-mail: mtp{at}uky.edu